These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35566802)

  • 1. COVID-19 Vaccination in Inflammatory Bowel Disease (IBD).
    Kubas A; Malecka-Wojciesko E
    J Clin Med; 2022 May; 11(9):. PubMed ID: 35566802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2-inactivated vaccine hesitancy and the safety in inflammatory bowel disease patients: a single-center study.
    Cao Y; Feng J; Duan S; Yang Y; Zhang Y
    Therap Adv Gastroenterol; 2022; 15():17562848221101722. PubMed ID: 35706827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID.
    Weaver KN; Zhang X; Dai X; Watkins R; Adler J; Dubinsky MC; Kastl A; Bousvaros A; Strople JA; Cross RK; Higgins PDR; Ungaro RC; Bewtra M; Bellaguarda E; Farraye FA; Boccieri ME; Firestine A; Kappelman MD; Long MD
    Inflamm Bowel Dis; 2022 Oct; 28(10):1497-1505. PubMed ID: 34871388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review Article: vaccination for patients with inflammatory bowel disease during the COVID-19 pandemic.
    Doherty J; Fennessy S; Stack R; O' Morain N; Cullen G; Ryan EJ; De Gascun C; Doherty GA
    Aliment Pharmacol Ther; 2021 Nov; 54(9):1110-1123. PubMed ID: 34472643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humoral Immunogenicity After Vaccination Against SARS-CoV-2 Infection in Inflammatory Bowel Disease Patients Under Immunosuppressive Therapy: Should We Prioritize an Additional Booster Injection?
    Macedo Silva V; Lima Capela T; Freitas M; Cúrdia Gonçalves T; Boal Carvalho P; Dias de Castro F; João Moreira M; Cotter J
    Inflamm Bowel Dis; 2023 Feb; 29(2):268-273. PubMed ID: 36099059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study.
    Cerna K; Duricova D; Lukas M; Machkova N; Hruba V; Mitrova K; Kubickova K; Kostrejova M; Teplan V; Vasatko M; Kastylova K; Lukas M
    Inflamm Bowel Dis; 2022 Oct; 28(10):1506-1512. PubMed ID: 34849919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementation and Short-term Adverse Events of Anti-SARS-CoV-2 Vaccines in Inflammatory Bowel Disease Patients: An International Web-based Survey.
    Ellul P; Revés J; Abreu B; Chaparro M; Gisbert JP; Allocca M; Fiorino G; Barberio B; Zingone F; Pisani A; Cassar D; Michalopoulos G; Mantzaris G; Koutroubakis I; Karmiris K; Katsanos K; Ďuricova D; Burisch J; Madsen GR; Maaser C; Naila A; Orfanoudaki E; Milivojevic V; Buisson A; Avedano L; Leone S; Torres J
    J Crohns Colitis; 2022 Aug; 16(7):1070-1078. PubMed ID: 35037033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients.
    Alexander JL; Mullish BH; Danckert NP; Liu Z; Olbei ML; Saifuddin A; Torkizadeh M; Ibraheim H; Blanco JM; Roberts LA; Bewshea CM; Nice R; Lin S; Prabhudev H; Sands C; Horneffer-van der Sluis V; Lewis M; Sebastian S; Lees CW; Teare JP; Hart A; Goodhand JR; Kennedy NA; Korcsmaros T; Marchesi JR; Ahmad T; Powell N
    EBioMedicine; 2023 Feb; 88():104430. PubMed ID: 36634565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 Vaccine Hesitancy among Patients with Inflammatory Bowel Disease Receiving Biologic Therapies in Kuwait: A Cross-Sectional Study.
    Shehab M; Zurba Y; Al Abdulsalam A; Alfadhli A; Elouali S
    Vaccines (Basel); 2021 Dec; 10(1):. PubMed ID: 35062716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement.
    Alexander JL; Moran GW; Gaya DR; Raine T; Hart A; Kennedy NA; Lindsay JO; MacDonald J; Segal JP; Sebastian S; Selinger CP; Parkes M; Smith PJ; Dhar A; Subramanian S; Arasaradnam R; Lamb CA; Ahmad T; Lees CW; Dobson L; Wakeman R; Iqbal TH; Arnott I; Powell N;
    Lancet Gastroenterol Hepatol; 2021 Mar; 6(3):218-224. PubMed ID: 33508241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of SARS-CoV-2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta-analysis and meta-regression.
    Bhurwal A; Mutneja H; Bansal V; Goel A; Arora S; Attar B; Minacapelli CD; Kochhar G; Chen LA; Brant S; Seril D
    Aliment Pharmacol Ther; 2022 May; 55(10):1244-1264. PubMed ID: 35355306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 vaccination rate and willingness of an additional dose among inflammatory bowel disease patients receiving biologic therapy: Fearless and with desire.
    Ramos L; Carrillo-Palau M; Alonso-Abreu I; Reygosa C; Hernández-Alvarez N; Amaral C; Hernández A; Benítez-Zafra F; Pérez-González F; Quintana-Díaz H; Hernandez-Guerra M
    Gastroenterol Hepatol; 2023 Apr; 46(4):255-260. PubMed ID: 35609791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The COVID-19 Vaccination Hesitancy Among the People With Inflammatory Bowel Disease in China: A Questionnaire Study.
    Wu X; Lin J; Buch H; Ding Q; Zhang F; Cui B; Ji G
    Front Public Health; 2021; 9():731578. PubMed ID: 34708016
    [No Abstract]   [Full Text] [Related]  

  • 14. SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systemic review and meta-analysis.
    Sung KY; Chang TE; Wang YP; Lin CC; Chang CY; Hou MC; Lu CL
    J Chin Med Assoc; 2022 Apr; 85(4):421-430. PubMed ID: 34974509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Misconceptions Drive COVID-19 Vaccine Hesistancy in Individuals with Inflammatory Bowel Disease.
    Zhang E; Gupta A; Al-Ani A; Macrae FA; Leong RW; Christensen B
    Can J Gastroenterol Hepatol; 2022; 2022():4527844. PubMed ID: 36124090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody Response to SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease: Results of a Single-Center Cohort Study in a Tertiary Hospital in Germany.
    Classen JM; Muzalyova A; Nagl S; Fleischmann C; Ebigbo A; Römmele C; Messmann H; Schnoy E
    Dig Dis; 2022; 40(6):719-727. PubMed ID: 34915480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
    Liu Z; Le K; Zhou X; Alexander JL; Lin S; Bewshea C; Chanchlani N; Nice R; McDonald TJ; Lamb CA; Sebastian S; Kok K; Lees CW; Hart AL; Pollok RC; Boyton RJ; Altmann DM; Pollock KM; Goodhand JR; Kennedy NA; Ahmad T; Powell N;
    Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):145-156. PubMed ID: 36481043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine Acceptance in Patients with Inflammatory Bowel Disease: Lessons Learned from the COVID-19 Pandemic.
    Mastrangeli G; Vernia F; Necozione S; Muselli M; Frassino S; Cesaro N; Latella G; Fabiani L
    Vaccines (Basel); 2024 May; 12(5):. PubMed ID: 38793802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic.
    Lin S; Lau LH; Chanchlani N; Kennedy NA; Ng SC
    Gut; 2022 Jul; 71(7):1426-1439. PubMed ID: 35477864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study.
    Liu Z; Alexander JL; Le K; Zhou X; Ibraheim H; Anandabaskaran S; Saifuddin A; Lin KW; McFarlane LR; Constable L; Seoane RC; Anand N; Bewshea C; Nice R; D'Mello A; Jones GR; Balarajah S; Fiorentino F; Sebastian S; Irving PM; Hicks LC; Williams HR; Kent AJ; Linger R; Parkes M; Kok K; Patel KV; Teare JP; Altmann DM; Boyton RJ; Hart AL; Lees CW; Goodhand JR; Kennedy NA; Pollock KM; Ahmad T; Powell N;
    EClinicalMedicine; 2023 Oct; 64():102249. PubMed ID: 37842172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.